Description

Rabeprazole Sodium USP

Rabeprazole Sodium USP is a high-purity, pharmaceutical-grade proton pump inhibitor used in oral dosage forms for the treatment of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related disorders. Compliant with United States Pharmacopeia (USP) standards, it provides potent and selective inhibition of gastric H⁺/K⁺-ATPase, resulting in effective suppression of gastric acid secretion. Rabeprazole Sodium
• Is a USP-compliant proton pump inhibitor for regulated pharmaceutical use
• Is used in oral tablets, capsules, and delayed-release formulations
• Reduces gastric acid secretion to manage GERD, ulcers, and hypersecretory disorders
• Provides rapid onset and prolonged acid suppression
• Is manufactured under Good Manufacturing Practice (GMP) certified conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Rabeprazole Sodium is chemically designated as sodium 2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole. It appears as a white to off-white crystalline powder that is sparingly soluble in water but suitable for incorporation into delayed-release oral dosage forms.
In pharmaceutical applications, Rabeprazole Sodium USP is used in:
• Oral delayed-release tablets and capsules for GERD and acid reflux
• Treatment of gastric and duodenal ulcers
• Therapy for Zollinger-Ellison syndrome and other hypersecretory conditions
• Combination therapy with antibiotics for Helicobacter pylori eradication
• Compounded and clinical research formulations for acid-related disorders
Rabeprazole Sodium USP selectively inhibits the proton pump of gastric parietal cells, reducing gastric acid secretion and providing symptom relief and ulcer healing. Its pharmacokinetic properties allow once-daily dosing in most clinical applications.
CarboMer supplies Rabeprazole Sodium USP with control over assay, polymorphic form, residual solvents, and microbial purity. Each batch meets USP monograph specifications and is suitable for regulated pharmaceutical development.
The material is packaged in sealed, moisture-resistant, tamper-evident containers. Available in laboratory, pilot, and commercial-scale quantities. Minimum order quantities (MOQ), lead times, and documentation including CoA and SDS are provided upon request.
Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), residual solvents, water content, heavy metals, and microbial limits. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer gastrointestinal APIs, Rabeprazole Sodium USP is supported by formulation guidance, regulatory expertise, and secure global supply to enable safe, effective, and compliant pharmaceutical products.